Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CHEK1 positive |
Therapy | CCT244747 + Paclitaxel + Radiotherapy |
Indication/Tumor Type | head and neck squamous cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CHEK1 positive | head and neck squamous cell carcinoma | sensitive | CCT244747 + Paclitaxel + Radiotherapy | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CCT244747, Taxol (paclitaxel), and radiation triple therapy synergistically inhibited Chek1 activation, and resulted in growth inhibition of head and neck squamous cell carcinoma cell lines in culture and in cell line xenograft models (PMID: 27422809). | 27422809 |
PubMed Id | Reference Title | Details |
---|---|---|
(27422809) | CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy. | Full reference... |